| Literature DB >> 26021203 |
Abstract
Approximately 10% to 15% of the chronic gastroesophageal reflux disease population is at risk for the development of Barrett's esophagus, particularly in the setting of other risk factors, including male gender, Caucasian race, age more than 50, and central obesity. The risk of cancer progression for patients with nondysplastic BE has been estimated to be approximately 0.2% to 0.5% per year. Given these low progression rates and the high cost of endoscopic surveillance, cost-effectiveness analyses in this area are useful to determine appropriate resource allocation.Entities:
Keywords: Ablation therapy; Barrett’s esophagus; Cost-effectiveness; Health-state utilities; Markov model
Mesh:
Year: 2015 PMID: 26021203 DOI: 10.1016/j.gtc.2015.02.011
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN: 0889-8553 Impact factor: 3.806